Middle Level LC-MS Characterization of Site-Specific and Random ADC

1 December 2017

Last month, the latest findings on antibody drug conjugates (ADCs) were presented at the European Antibody Congress in Basel, Switzerland.

Genovis AB exhibited our joint poster titled “Middle Level LC-MS Characterization of Site-Specific and Random ADC – Impact of Conjugation Method on In Vivo Tumor Uptake”.

In this work Alphalyse and Genovis AB collaborated on characterizing the drug conjugation subunit localization of trastuzumab emtansine (TDM-1), and trastuzumabconjugated with MMAE using the site-specific GlyCLICK technology by middle-level LC-MS.

Download poster